Redcare Pharmacy N.V. announces guidance for 2026.

Redcare Pharmacy N.V. / NL0012044747

EQS-Ad-hoc: Redcare Pharmacy N.V. / Key word(s): Forecast / Full year


03-March-2026 / 22:32 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

---

  Sevenum, the Netherlands, March 3, 2026. The Management Board of Redcare Pharmacy N.V. has determined its guidance for 2026: Total revenue growth of 13% to 15%. Rx revenue in Germany in excess of EUR 670 million. Non-Rx revenue growth of 8% to 10%. Adjusted EBITDA margin of at least 2.5%.
Contact:
rikutis consulting
Thomas Schnorrenberg
Cel: [phone]
E-Mail: [e-mail]

End of Inside Information

---

03-March-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News

---

Language:	English
Company:	Redcare Pharmacy N.V.
	Erik de Rodeweg 11-13
	5975 WD Sevenum
	Netherlands
Phone:	0800 - 200 800 300
Fax:	0800 - 90 70 90 20
E-mail:	[e-mail]
Internet:	www.redcare-pharmacy.com
ISIN:	NL0012044747, DE000A19Y072
WKN:	A2AR94, A19Y072
Indices:	MDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
EQS News ID:	2285154

End of Announcement	EQS News Service

---

2285154  03-March-2026 CET/CEST